CRMDCorMedix Inc.
$7.84-30% 1Y
$7.84
$6.2552 weeks$12.73
CRMD in its own filings
CRMD's filing record carries 3 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
434
Events found in the filings · across 1,135 filings · the record starts in 2009
- Hard flags
- 3
Hard flags
- Most recent filing
- Oct 19, 2026
Most recent filing · Form 8-K
- Record starts
- Dec 22, 2009
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 11, 2026
- Change in certifying accountant4 occurrences
- 2026-07-01
- Late periodic reporthistorical
- 2013-11-14
- Delisting notice / listing-rule failure12 occurrences
- 2018-08-31
- Security removed from listing or deregistered3 occurrences · usually a matured note or preferred class, not the common shares
- 2021-02-01
- SEC comment-letter activity24 occurrences
- 2024-05-20
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 19, 2026NJ – October 19, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today announced that the U.S. Food and Drug Administration.Regulation FD disclosure · press release
- Aug 7, 2026On July 24, 2026, the U.S. District Court for the District of New Jersey (the “District Court”) issued an order granting preliminary approval of the proposed settlement of the consolidated derivative lawsuit captioned In re CorMedix Inc. Derivative Litigation, Case No. 2:21-cv-18493-JXN-LDW (D.N.J) and a related …Other event · Form 8-K
- Jul 2, 2026On June 29, 2026, CorMedix Inc. (the “Company”) effected a change in its executive leadership structure, whereby the Company’s Board of Directors has appointed Elizabeth Hurlburt, currently the Chief Operating Officer, to the newly created role of Chief Operating and Commercial Officer where she will have functional …Other event · Form 8-K
- Jul 1, 2026Dismissal of Independent Registered Public Accounting Firm On June 25, 2026, the Audit Committee of the Board of Directors of CorMedix Inc. (the “Company”) approved the decision to change its independent registered public accounting firm and dismissed CBIZ CPAs P.C. (“CBIZ CPAs”) as the Company’s independent …Auditor change · Form 8-K
- Jun 8, 2026NJ – June 8, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today announced that.Regulation FD disclosure · press release
- Apr 27, 2026CORMEDIX Therapeutics AnnounceS POSITIVE Topline Results from PHASE III respect TriaL assessing Rezzayo® for the PROPHYLAXIS of.Regulation FD disclosure · press release
- Mar 5, 2026Inc. Reports FOURTH Quarter AND FULL YEAR 2025 Financial Results and provides business update.Earnings release · press release
- Jan 8, 2026On January 5, 2026, the Company entered into an amended and restated executive employment agreement (the “A&R Employment Agreement”) with Joseph Todisco, the Company’s Chief Executive Officer.Earnings release · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…